key: cord-0917592-p8t9nfaw
authors: Farmakis, Ioannis; Kosmidis, Diamantis; Liantzakis, Christos; Serasli, Evangelia; Karvounis, Haralambos; Koutsakis, Athanasios; Giannakoulas, George
title: The spectrum of COVID-19 in complex adult congenital heart disease: a case series
date: 2021-02-18
journal: International journal of cardiology. Congenital heart disease
DOI: 10.1016/j.ijcchd.2021.100097
sha: a04823f6cdc33d34079d280d9917149d8b0203b4
doc_id: 917592
cord_uid: p8t9nfaw

nan

The coronavirus disease 2019 (COVID-19) pandemic has proven to be a significant challenge both for physicians and patients with chronic conditions. There is a continuous flow of data for patients with congenital heart disease, however resources are limited and recommendations rely mainly on expert opinion 2 . Complex adult congenital heart disease (ACHD) patients represent a highly heterogenous population with great anatomical complexity and are considered a high-risk group for complications associated with COVID-19 1 . Herein, we present five cases of complex ACHD diagnosed with COVID-19 (Table) . Informed consent has been obtained from each patient presented.

A 35-year old male with a history of Eisenmenger syndrome in the setting of unrepaired ventricular septal defect (VSD) and atrial septal defect (ASD) was presented to the emergency department because of persistent fever and productive cough. He had already been diagnosed positive with SARS-CoV-2 infection ten days ago. Vitals at admission revealed oxygen desaturation at 74% with a baseline SO 2 at 80%, without respiratory distress. An ECG was performed and revealed the known right ventricular hypertrophy patient's pattern with no ischaemic or arrhythmic alterations. The admission laboratory tests were significant for increased LDH and CRP values, without lymphopenia and increased haemoglobin 18.9 g/dl. NT-proBNP was 108 pg/ml. A chest CT was performed and revealed extensive bilateral lesions compatible with COVID-19 ( Figure) . The patient required oxygen therapy via a face mask (he could not tolerate nasal cannula) at 5L/min to achieve oxygen saturation 80-85%. He was started on remdesivir, dexamethasone, ampicillin/sulbactam and azithromycin. His baseline medication included bosentan and acenocoumarol, which were continued. Throughout hospitalization he was clinically stable, progressively tapered off oxygen therapy and was discharged after 7 days.

A 28-year old male with a history of transposition of the great arteries and atrial switch operation was presented to the emergency department due to fever. Rapid antigen SARS-CoV-2 testing was positive and was later confirmed by RT-PCR testing. Arterial blood gases showed satisfactory partial pressure of oxygen 78 mmHg on air. Laboratory measurements included mildly increased CRP, LDH and d-dimer levels and reduced lymphocyte count but normal ferritin levels. BNP at admission was 275 pg/ml (baseline NT-proBNP was 636 pg/ml). A chest CT revealed small areas of ground glass opacity bilaterally and mainly in the right lower pulmonary lobe (Figure) . An echocardiogram was performed at the COVID-19 ward and was not altered from baseline, namely a hypertrophied and dilated systemic right ventricle with moderate systolic dysfunction and severe systemic atrioventricular valve regurgitation. The patient was started on ceftriaxone, azithromycin and low molecular weight heparin and continued baseline therapy with b-blocker, sacubitril/valsartan, eplerenone and furosemide. He did not require any oxygen therapy throughout his stay. His hospitalization lasted 8 days and was discharged in a stable condition.

Three patients with complex ACHD were diagnosed with COVID-19 and were managed at home (Table) . All patients reported fever, one patient fatigue and another sore throat. None experienced dyspnoea, chest pain or arrhythmia during the disease. They were instructed to an every-day measurement of oxygen saturation and early admission in case of deterioration. The median symptomatic duration was 6 days and all patients completed a 14-day self-isolation uneventfully.

Teleconsultation for all infected patients has been scheduled one month after the infection in order to evaluate their post-COVID clinical status. 

Adult congenital heart disease and the COVID-19 pandemic

Coronavirus disease 2019 in adults with congenital heart disease: a position paper from the ESC working group of adult congenital heart disease, and the International Society for Adult Congenital Heart Disease

Impact of Coronavirus Disease 2019 (COVID-19) on Patients With Congenital Heart Disease Across the Lifespan: The Experience of an Academic Congenital Heart Disease Center

Association for European Paediatric and Congenital Cardiology (AEPC), and the European Society of Cardiology (ESC) Working Group on Grown-up Congenital heart disease

The globe on the spotlight: Coronavirus disease 2019 (Covid-19)

COVID-19 Treatment Guidelines

COVID-19 and congenital heart disease: an insight of pathophysiology and associated risks. Cardiol Young

Acute Increase in Deaths Among Patients With Adult Congenital Heart Disease During COVID-19

Physical activity assessment and advice as part of routine clinical care in patients with congenital heart disease

Adult congenital heart care in the COVID-19 era, and beyond: A call for action

J o u r n a l P r e -p r o o f

☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.☐The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:J o u r n a l P r e -p r o o f